Treatment of Systemic Lupus Erythematosus by inhibition of T cell costimulation with anti-CD154: A randomized, double-blind, placebo-controlled trial

Arthritis and Rheumatism

Volumn 46, Issue 12, 2002, Pages 3251-3258

  Kalunian, Kenneth C ^a,e   Davis Jr , John C ^b   Merrill, Joan T ^c   Totoritis, Mark C ^d   Wofsy, David ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

^d BIOGEN   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD40 LIGAND MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY IDEC 131; PLACEBO; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; AGED; ARTHRALGIA; ARTICLE; BACKACHE; BRONCHITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DERMATITIS; DIARRHEA; DISEASE ACTIVITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG INFUSION; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; DYSURIA; FATIGUE; FEMALE; HEADACHE; HERPES ZOSTER; HUMAN; IMMUNOGENICITY; LIMB PAIN; LUNG CARCINOMA; MAJOR CLINICAL STUDY; MALE; MENIERE DISEASE; MIGRAINE; MULTICENTER STUDY; NAUSEA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; SINUSITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE ACTIVATION; THORAX PAIN; TOTAL HIP PROSTHESIS; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VOMITING;

ADULT; AGED; ANTIBODIES, MONOCLONAL; CD40 LIGAND; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; PLACEBOS; SAFETY; T-LYMPHOCYTES; TREATMENT OUTCOME;

EID: 0036899589     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.10681     Document Type: Article

References (26)

1. Klippel JH. Systemic lupus erythematosus: Treatment-related complications superimposed on chronic disease. JAMA 1990;263: 1812-5.
2. Koshy M, Berger D, Crow MK. Increased expression of CD40 ligand on systemic lupus erythematosus lymphocytes. J Clin Invest 1996;98:826-37.
3. Daikh DI, Finck BK, Linsley PS, Hollenbaugh D, Wofsy D. Long-term inhibition of murine lupus by brief simultaneous blockade of the B7/CD28 and CD40/gp39 costimulation pathways. J Immunol 1997;159:3104-8.
4. Mohan C, Shi Y, Laman JD, Datta SK. Interaction between CD40 and its ligand gp39 in the development of murine lupus nephritis. J Immunol 1995;154:1470-80.
5. Janeway CA Jr, Bottomly K. Signals and signs for lymphocyte responses. Cell 1994;76:275-85.
6. Jenkins MK. The ups and downs of T cell costimulation. Immunity 1994;1:443-6.
7. Grewal IS, Flavell RA. CD40 and CD154 in cell-mediated immunity. Annu Rev Immunol 1998;16:111-35.
8. Noelle R, Ledbetter J, Aruffo A. CD40 and its ligand, an essential ligand-receptor pair for thymus-dependent B-cell activation. Immunol Today 1992;13:431-3.
9. Durie FH, Foy TM, Masters SR, Laman JD, Noelle RJ. The role of CD40 in the regulation of humoral and cell-mediated immunity. Immunol Today 1994;15:406-11.
10. Buhlmann JE, Foy TM, Aruffo A, Crassi KM, Ledbetter JA, Green WR, et al. In the absence of a CD40 signal, B cells are tolerogenic. Immunity 1995;2:645-53.
11. Mach F, Schonbeck U, Sukhova GK, Bourciev T, Bonnefiy JY, Pober JS, et al. Functional CD40 ligand is expressed on human vascular endothelial cells, smooth muscle cells, and macrophages: Implications for CD40-CD40 ligand signaling in atherosclerosis. Proc Natl Acad Sci U S A 1997;94:1931-6.
12. Desai-Mehta A, Lu L, Ramsey-Goldman R, Datta SK. Hyperexpression of CD40 ligand by B and T cells in human lupus and its role in pathogenic autoantibody production. J Clin Invest 1996;97: 2063-73.
13. Kato K, Santana-Sahagun E, Rassenti L, Weisman MH, Tumura N, Kobayashi S, et al. The soluble CD40 ligand sCD154 in systemic lupus erythematosus. J Clin Invest 1999;104:947-55.
14. Foy TM, Aruffo A, Bajorath J, Buhlmann JE, Noelle RJ. Immune regulation by CD40 and its ligand GP39. Annu Rev Immunol 1996;14:591-617.
15. Anderson D, Kloetzer W, Hanna N. Effects of IDEC-131 on induction of inflammatory and procoagulant phenotypes of activated human endothelial cells [abstract]. Arthritis Rheum 2000;43 Suppl 9:S51.
16. Anderson D, Pan L-Z, Hanna N. IDEC-131 anti-CD40L monoclonal antibody is a nonagonist of human T lymphocyte activation [abstract]. Arthritis Rheum 2000;43 Suppl 9:S51.
17. Davis JC, Totoritis MC, Rosenberg J, Sklenar TA, Wofsy D. Phase I clinical trial of a monoclonal antibody against CD40-ligand (IDEC-131) in patients with systemic lupus erythematosus. J Rheumatol 2001;28:95-101.
18. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7.
19. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter]. Arthritis Rheum 1997;40:1725.
20. Petri M, Buyon J, Skovron ML. Disease activity and health status (SF-36) in postmenopausal systemic lupus erythematosus: The SELENA trial [abstract]. Arthritis Rheum 1997;40 Suppl 9:S208.
21. Symmons DPM, Coppock JS, Bacon PA, Bresnihan B, Isenberg DA, Maddison P, et al. Development and assessment of a computerized index of clinical disease activity in systemic lupus erythematosus. Q J Med 1988;69:927-37.
22. Petri M, Buyon J, Skovron ML. Reliability of SELENA SLEDAI and flare as clinical trial outcome measures [abstract]. Arthritis Rheum 1998;41(Suppl):S218.
23. Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD. The fatigue severity scale: Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol 1989;46:1121-3.
24. Stoll T, Gordon C, Seifert B, Richardson K, Malik J, Bacon PA, et al. Consistency and validity of patient administered assessment of quality of life by the MOS SF-36: Its association with disease activity and damage in patients with systemic lupus erythematosus. J Rheumatol 1997;24:1608-14.
25. Kawai T, Andrews D, Colvin RB, Sachs DH, Cosimi AB. Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand [abstract]. Nat Med 2000;6:114.
26. Mease PJ, Merrill JT, Lahita RG, Petri MA, Ginzler EM, Katz RS, et al. GL701 (Prasterone, dehydroepiandrosterone) improves systemic lupus erythematosus [abstract]. Arthritis Rheum 2000;43 Suppl 9:S271.